

MEDICATION NAME:	AVATROMBOPAG BRAND: DOPLETET
HOW IS IT GIVEN:	Oral tablet or Sprinkle formulation
HOW DOES IT WORK:	Binds to the thrombopoietin receptor on megakaryocytes which stimulates platelet production.
COMMON DOSING REGIMENS:	<p><u>Starting dose:</u></p> <ul style="list-style-type: none"> • Ages 1 to <6 years: 10 mg once a day. • Age ≥6 years: 20 mg once a day. <p><u>Maximum dose :</u></p> <ul style="list-style-type: none"> • Ages 1 to <6 years: 20 mg once a day. • Age ≥6 years: 40 mg once a day. <p>Dosage should be lowered if the platelet count exceeds 400 x10⁹/L. Dose modifications can be made by changing the total weekly dose.</p>
COMMON SIDE EFFECTS:	Headache, joint ache, abdominal pain
RARE BUT SERIOUS SIDE EFFECTS:	The risk of thrombosis (blood clots) and bone marrow reticulosis (fibrous scarring) has not been established.
TYPICAL TIME TO RESPONSE:	1-3 weeks.
LIKELIHOOD OF INITIAL RESPONSE:	Approximately 56% of patients attain a platelet count of 50 x 10 ⁹ /L or greater on day 8.
LIKELIHOOD OF LONG-TERM RESPONSE (3-5 YEARS):	With ongoing treatment, platelet response continues in most individuals.
OTHER CONSIDERATIONS:	To be taken with food (no dietary limitations). The prevalence of sustained remission off treatment has not been established. Not recommended for use during pregnancy.

References

1. Grace RF, et al. Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVAPED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. *Lancet Haematol.* 2025 Jul;12(7):e494-e504.
2. Grace RF, et al. Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary. *Expert Rev Hematol.* 2025 Dec 18:1-10.
3. Wang N, et al. Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational study. *Br J Haematol.* 2025 Mar;206(3):935-943.
4. Harris EM, et al. Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia. *Pediatr Blood Cancer.* 2025 Nov 10:e32143.
5. Ghanima, W et al. "Thrombopoietin receptor agonists: ten years later." *Haematologica.* 2019 Jun; 104(6): 1112-1123.
6. Jurczak, W et al. "Phase 3 randomized study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia." *British Journal of Haematology.* 2018 Nov; 183(3): 479-490.
7. Platelet disorder support association: <https://www.pdsa.org/platelet-growth-factors.html>
8. <https://www.chemoexperts.com/avatrombopag-doptelet-itp.html>